Drugs / S42909
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03077165 | Sep 2017 → Dec 2019 | ulcer of lower limbs | Ilkos Therapeutic Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S42909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03077165 ↗ |
| Action | Inhibit | “S42909 is an inhibitor of β-Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase” NCT03077165 ↗ |
| Route | Oral | “per os administration” NCT03077165 ↗ |